Primal P Singh1, Daniel P Lemanu2, Mattias Soop3, Ian P Bissett4, Jeff Harrison5, Andrew G Hill2. 1. Department of Surgery, South Auckland Clinical School, Faculty of Medical and Health Sciences, Auckland, New Zealand. Electronic address: dr.parrysingh@gmail.com. 2. Department of Surgery, South Auckland Clinical School, Faculty of Medical and Health Sciences, Auckland, New Zealand. 3. Department of Surgery, North Shore Hospital, Waitemata District Health Board, Auckland, New Zealand. 4. Department of Surgery, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand. 5. School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Abstract
BACKGROUND: Statins have numerous potential benefits relevant to abdominal surgery, and their use has been associated with a reduction in the systemic inflammatory response syndrome, wound infection, and anastomotic leak after colorectal surgery. However, this clinical evidence is limited to retrospective studies. The aim of this study was to prospectively investigate whether perioperative statin therapy can decrease the incidence of complicationsafter major colorectal surgery. STUDY DESIGN: A prospective, double-blind, parallel-group, randomized controlled trial was conducted at 3 tertiary hospitals in New Zealand, between October 2011 and August 2013. Adult patients undergoing elective colorectal resection for any indication or reversal of Hartmann's procedure were randomized with a 1:1 patient allocation ratio to receive either 40 mg oral simvastatin or placebo once daily for 3 to 7 days preoperatively until 14 days postoperatively. The primary outcome was the overall incidence of complications for 30 days postoperatively. Secondary outcomes included the systemic and peritoneal cytokine response (interleukin [IL]-1α, IL-1β, IL-6, IL-8, IL-10, tumor necrosis factor [TNF]α) on postoperative day 1. RESULTS: There were 132 patients included in the study (65simvastatin, 67 placebo). There were no significant differences between the 2 groups at baseline with regard to patient, operation, and disease characteristics. There were no significant differences between the 2 groups in the incidence, grade, and type of postoperative complications (simvastatin: 44 [68%] vs placebo: 50 [75%], odds ratio 0.71 [95% CI 0.33 to 1.52], p = 0.444). Plasma concentrations of IL-6, IL-8, and TNFα, and peritoneal concentrations of IL-6 and IL-8, were significantly lower in the simvastatin group postoperatively. CONCLUSIONS:Perioperative simvastatin therapy in major colorectal surgery attenuates the early proinflammatory response to surgery, but there were no differences in postoperative complications.
RCT Entities:
BACKGROUND: Statins have numerous potential benefits relevant to abdominal surgery, and their use has been associated with a reduction in the systemic inflammatory response syndrome, wound infection, and anastomotic leak after colorectal surgery. However, this clinical evidence is limited to retrospective studies. The aim of this study was to prospectively investigate whether perioperative statin therapy can decrease the incidence of complications after major colorectal surgery. STUDY DESIGN: A prospective, double-blind, parallel-group, randomized controlled trial was conducted at 3 tertiary hospitals in New Zealand, between October 2011 and August 2013. Adult patients undergoing elective colorectal resection for any indication or reversal of Hartmann's procedure were randomized with a 1:1 patient allocation ratio to receive either 40 mg oral simvastatin or placebo once daily for 3 to 7 days preoperatively until 14 days postoperatively. The primary outcome was the overall incidence of complications for 30 days postoperatively. Secondary outcomes included the systemic and peritoneal cytokine response (interleukin [IL]-1α, IL-1β, IL-6, IL-8, IL-10, tumor necrosis factor [TNF]α) on postoperative day 1. RESULTS: There were 132 patients included in the study (65 simvastatin, 67 placebo). There were no significant differences between the 2 groups at baseline with regard to patient, operation, and disease characteristics. There were no significant differences between the 2 groups in the incidence, grade, and type of postoperative complications (simvastatin: 44 [68%] vs placebo: 50 [75%], odds ratio 0.71 [95% CI 0.33 to 1.52], p = 0.444). Plasma concentrations of IL-6, IL-8, and TNFα, and peritoneal concentrations of IL-6 and IL-8, were significantly lower in the simvastatin group postoperatively. CONCLUSIONS: Perioperative simvastatin therapy in major colorectal surgery attenuates the early proinflammatory response to surgery, but there were no differences in postoperative complications.
Authors: Arvid Pourlotfi; Rebecka Ahl; Gabriel Sjolin; Maximilian Peter Forssten; Gary A Bass; Yang Cao; Peter Matthiessen; Shahin Mohseni Journal: Colorectal Dis Date: 2020-12-23 Impact factor: 3.788
Authors: Alessandro Putzu; Carolina Maria Pinto Domingues de Carvalho E Silva; Juliano Pinheiro de Almeida; Alessandro Belletti; Tiziano Cassina; Giovanni Landoni; Ludhmila Abrahao Hajjar Journal: Ann Intensive Care Date: 2018-09-27 Impact factor: 6.925
Authors: Jean F Hamel; Charles Sabbagh; Arnaud Alves; Jean M Regimbeau; Timothée Vignaud; Aurélien Venara Journal: Sci Rep Date: 2021-04-01 Impact factor: 4.379
Authors: Erik Stenberg; Luiz Fernando Dos Reis Falcão; Mary O'Kane; Ronald Liem; Dimitri J Pournaras; Paulina Salminen; Richard D Urman; Anupama Wadhwa; Ulf O Gustafsson; Anders Thorell Journal: World J Surg Date: 2022-01-04 Impact factor: 3.352
Authors: Chunxia Shi; Zugui Zhang; Jordan Goldhammer; David Li; Bob Kiaii; Victor Rudriguez; Douglas Boyd; David Lubarsky; Richard Applegate; Hong Liu Journal: BMC Anesthesiol Date: 2022-04-26 Impact factor: 2.376
Authors: Bruce Su'a; Tony Milne; Rebekah Jaung; Weisi Xia; James Jin; Darren Svirskis; Tim Eglinton; Ian Bissett; Andrew G Hill Journal: ANZ J Surg Date: 2022-04-28 Impact factor: 2.025